• Prescribing Information
  • Patient Site
  • Sign up for emails
  • Request a representative
Approved use for Talicia

Talicia is indicated for the treatment of Helicobacter pylori infection in adults

Talicia
  • About
    • H. pylori resistance
    • How Talicia works
  • Efficacy
    • Talicia eradication rates
    • Traditional therapy failure rates
  • Safety
  • Simple Dosing
  • HCP Resources
    • Request information
    • Patient resources
    • FAQs
  • About
    ▽
    • H. pylori resistance
    • How Talicia works
  • Efficacy
    ▽
    • Talicia eradication rates
    • Traditional therapy failure rates
  • Safety
  • Simple Dosing
  • HCP Resources
    ▽
    • Request information
    • Patient resources
    • FAQs

Slide

Slide Eradication Starts HereTM
Discover high eradication rates
Find out how your patients can save on Talicia
Request a representative
+ -
Important Safety Information About Talicia

Talicia contains omeprazole, a proton pump inhibitor (PPI), amoxicillin, a penicillin-class antibacterial, and rifabutin, a rifamycin antibacterial. It is contraindicated in patients with known hypersensitivity to any of these medications, any other components of the formulation, any other beta-lactams or any other rifamycins.

Talicia is contraindicated in patients receiving delavirdine, voriconazole or rilpivirine-containing products.

Serious and occasionally fatal hypersensitivity reactions have been reported with omeprazole, amoxicillin and rifabutin.

Acute Tubulointerstitial Nephritis has been observed in patients taking PPIs and penicillins.

Clostridioides difficile-associated diarrhea has been reported with use of nearly all antibacterial agents and may range from mild diarrhea to fatal colitis.

Talicia may cause fetal harm and is not recommended for use in pregnancy. It may also reduce the efficacy of hormonal contraceptives. An additional non-hormonal method of contraception is recommended when taking Talicia.

Talicia should not be used in patients with hepatic impairment or severe renal impairment.

Cutaneous lupus erythematosus and systemic lupus erythematosus have been reported in patients taking PPIs. These events have occurred as both new onset and exacerbation of existing autoimmune disease.

The most common adverse reactions (≥1%) were diarrhea, headache, nausea, abdominal pain, chromaturia, rash, dyspepsia, oropharyngeal pain, vomiting, and vulvovaginal candidiasis.

INDICATION

TALICIA® (omeprazole magnesium, amoxicillin and rifabutin) delayed-release capsules are indicated for the treatment of Helicobacter pylori infection in adults.

You are encouraged to report Adverse Reactions to RedHill Biopharma Inc. at 1-833-ADRHILL (1-833-237-4455) or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

This site is intended for US health care professionals only.

*Plans and coverage may vary and subject to change. General information only, not a guarantee of coverage. Coverage and status do not imply efficacy or safety.

HCP Address

RedHill Biopharma Inc. (U.S. Office)
8045 Arco Corporate Drive, Suite 200
Raleigh, NC 27617
Tel: +1-984-444-7010
Fax: +1-919-406-0400
[email protected]

Back to top
  • Contact Us
  • RedHill Biopharma US Corporate Site
  • Privacy Policy
  • Terms of Use
  • Sitemap
  • Sitemap
  • Prescribing Information

Trademarks are owned by or licensed to RedHill Biopharma Inc. or its related companies.

©2021 RedHill Biopharma Ltd. All rights reserved. US-TAL-139 06/2021

Exciting national formulary coverage news!

Talicia is a PREFERRED BRAND on:
The Express Scripts National Preferred Formulary
The Prime Therapeutics’ NetResults A-Series National Formulary
Serving 23 Blue Cross Blue Shield plans*

The information on the following site is intended for US health care professionals. Please choose:

I am not a US health care professional

GO BACK

I am a US health care professional

CONTINUE

The information on the following site is intended for US health care professionals. Please choose:

I am not a US health care professional

GO BACK

I am a US health care professional

CONTINUE